Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CollPlant Biotechnologies (CLGN) Gains from Investment Securities (2019 - 2024)

Historic Gains from Investment Securities for CollPlant Biotechnologies (CLGN) over the last 4 years, with Q4 2024 value amounting to $50500.0.

  • CollPlant Biotechnologies' Gains from Investment Securities fell 6803.8% to $50500.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $50500.0, marking a year-over-year decrease of 6803.8%. This contributed to the annual value of $50500.0 for FY2024, which is 6803.8% down from last year.
  • According to the latest figures from Q4 2024, CollPlant Biotechnologies' Gains from Investment Securities is $50500.0, which was down 6803.8% from $158000.0 recorded in Q4 2023.
  • In the past 5 years, CollPlant Biotechnologies' Gains from Investment Securities ranged from a high of $258000.0 in Q4 2021 and a low of $50500.0 during Q4 2024
  • Moreover, its 3-year median value for Gains from Investment Securities was $110000.0 (2021), whereas its average is $127583.3.
  • Examining YoY changes over the last 5 years, CollPlant Biotechnologies' Gains from Investment Securities showed a top increase of 6803.8% in 2024 and a maximum decrease of 6803.8% in 2024.
  • Quarter analysis of 3 years shows CollPlant Biotechnologies' Gains from Investment Securities stood at $258000.0 in 2021, then tumbled by 38.76% to $158000.0 in 2023, then crashed by 68.04% to $50500.0 in 2024.
  • Its Gains from Investment Securities stands at $50500.0 for Q4 2024, versus $158000.0 for Q4 2023 and $258000.0 for Q4 2021.